Aerobic Exercise Performance and Muscle Strength in Statin Users—The LIFESTAT Study
INTRODUCTIONStatins are widely used in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) which can affect muscle function and levels of physical activity. We investigated whether statin-associated myalgia is coupled to impaired...
Gespeichert in:
| Veröffentlicht in: | Medicine and science in sports and exercise 2019-07, Vol.51 (7), p.1429-1437 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1437 |
|---|---|
| container_issue | 7 |
| container_start_page | 1429 |
| container_title | Medicine and science in sports and exercise |
| container_volume | 51 |
| creator | MORVILLE, THOMAS DOHLMANN, TINE LOVSØ KUHLMAN, ANJA BIRK SAHL, RONNI EG KRIEGBAUM, MARGIT LARSEN, STEEN DELA, FLEMMING HELGE, JØRN WULFF |
| description | INTRODUCTIONStatins are widely used in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) which can affect muscle function and levels of physical activity. We investigated whether statin-associated myalgia is coupled to impaired aerobic exercise performance including fat oxidation as well as impaired muscle strength.
METHODSA population-based survey (6000 people) was performed to assess the prevalence of statin-associated myalgia in the Danish population. In addition, 64 statin users in primary prevention with myalgia (M; n = 25; 61 ± 1 yr) or without myalgia (NM; n = 37; 63 ± 1 yr) as well as a control group not taking statins (C; n = 20; 60 ± 2 yr) were enrolled in a cross-sectional study where they performed aerobic exercise and muscle strength tests.
RESULTSThe response rate for the survey was 51% and data showed a prevalence of statin-associated myalgia in 19% of responders using statins. The experimental study showed no difference between the groups in aerobic capacity (C, 29 ± 1 mL O2·min·kg; M, 27 ± 1 mL O2·min·kg; NM, 28 ± 1 mL O2·min·kg) or maximal fat oxidation (C, 247 ± 26 mg·min; M, 295 ± 24 mg·min; NM, 279 ± 17 mg·min). Measurements of strength were similar in all three groups including rate of force development (C, 795 ± 56 N·m·s; M, 930 ± 93 N·m·s; NM, 971 ± 57 N·m·s) and leg extension power (C2.6 ± 0.2; M2.3 ± 0.1; NM2.4 ± 0.1 W·kg). All results are mean ± SEM.
CONCLUSIONStatin users in primary prevention experiencing myalgia do not have impaired aerobic exercise performance or muscle strength compared to nonmyalgic statin users or control subjects. |
| doi_str_mv | 10.1249/MSS.0000000000001920 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2242828324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2242828324</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4020-2eccb1dfbe09407759ccb0534164466f103e541e97a32eb46b0877530ca77c803</originalsourceid><addsrcrecordid>eNp9kEtOwzAQhi0EoqVwA4SyZJPiV17LqmqhUiuQkq4tx5mQQB7FTlS64xCckJNg1IIQC2YzY_v7x9KH0CXBY0J5dLOK4zH-VSSi-AgNicewixnxjtHQ3nluRBgZoDNjniwUMEZO0YARSrDPwyFaT0C3aamc2StoVRpwHkDnra5lo8CRTeaseqMqcOJOQ_PYFU7Z2Fl2tq0NaPPx9p4U4CwX81mcTBL71me7c3SSy8rAxaGP0Ho-S6Z37vL-djGdLF3FMcUuBaVSkuUp4IjjIPAie8Ye48Tn3Pdzghl4nEAUSEYh5X6KQ0sxrGQQqBCzEbre793o9qUH04m6NAqqSjbQ9kZQymlIQ0a5RfkeVbo1RkMuNrqspd4JgsWXUGGFir9Cbezq8EOf1pD9hL4NWiDcA9u26qyP56rfghYFyKor_t_9CcbngLY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242828324</pqid></control><display><type>article</type><title>Aerobic Exercise Performance and Muscle Strength in Statin Users—The LIFESTAT Study</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Journals@Ovid Complete</source><creator>MORVILLE, THOMAS ; DOHLMANN, TINE LOVSØ ; KUHLMAN, ANJA BIRK ; SAHL, RONNI EG ; KRIEGBAUM, MARGIT ; LARSEN, STEEN ; DELA, FLEMMING ; HELGE, JØRN WULFF</creator><creatorcontrib>MORVILLE, THOMAS ; DOHLMANN, TINE LOVSØ ; KUHLMAN, ANJA BIRK ; SAHL, RONNI EG ; KRIEGBAUM, MARGIT ; LARSEN, STEEN ; DELA, FLEMMING ; HELGE, JØRN WULFF</creatorcontrib><description>INTRODUCTIONStatins are widely used in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) which can affect muscle function and levels of physical activity. We investigated whether statin-associated myalgia is coupled to impaired aerobic exercise performance including fat oxidation as well as impaired muscle strength.
METHODSA population-based survey (6000 people) was performed to assess the prevalence of statin-associated myalgia in the Danish population. In addition, 64 statin users in primary prevention with myalgia (M; n = 25; 61 ± 1 yr) or without myalgia (NM; n = 37; 63 ± 1 yr) as well as a control group not taking statins (C; n = 20; 60 ± 2 yr) were enrolled in a cross-sectional study where they performed aerobic exercise and muscle strength tests.
RESULTSThe response rate for the survey was 51% and data showed a prevalence of statin-associated myalgia in 19% of responders using statins. The experimental study showed no difference between the groups in aerobic capacity (C, 29 ± 1 mL O2·min·kg; M, 27 ± 1 mL O2·min·kg; NM, 28 ± 1 mL O2·min·kg) or maximal fat oxidation (C, 247 ± 26 mg·min; M, 295 ± 24 mg·min; NM, 279 ± 17 mg·min). Measurements of strength were similar in all three groups including rate of force development (C, 795 ± 56 N·m·s; M, 930 ± 93 N·m·s; NM, 971 ± 57 N·m·s) and leg extension power (C2.6 ± 0.2; M2.3 ± 0.1; NM2.4 ± 0.1 W·kg). All results are mean ± SEM.
CONCLUSIONStatin users in primary prevention experiencing myalgia do not have impaired aerobic exercise performance or muscle strength compared to nonmyalgic statin users or control subjects.</description><identifier>ISSN: 0195-9131</identifier><identifier>EISSN: 1530-0315</identifier><identifier>DOI: 10.1249/MSS.0000000000001920</identifier><identifier>PMID: 31210648</identifier><language>eng</language><publisher>United States: American College of Sports Medicine</publisher><subject>Cardiovascular Diseases - prevention & control ; Cross-Sectional Studies ; Exercise Tolerance - drug effects ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Lipid Metabolism ; Male ; Middle Aged ; Muscle Strength - drug effects ; Myalgia - chemically induced ; Myosin Heavy Chains - metabolism ; Primary Prevention ; Simvastatin - adverse effects ; Simvastatin - pharmacology</subject><ispartof>Medicine and science in sports and exercise, 2019-07, Vol.51 (7), p.1429-1437</ispartof><rights>2019 American College of Sports Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4020-2eccb1dfbe09407759ccb0534164466f103e541e97a32eb46b0877530ca77c803</citedby><cites>FETCH-LOGICAL-c4020-2eccb1dfbe09407759ccb0534164466f103e541e97a32eb46b0877530ca77c803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31210648$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MORVILLE, THOMAS</creatorcontrib><creatorcontrib>DOHLMANN, TINE LOVSØ</creatorcontrib><creatorcontrib>KUHLMAN, ANJA BIRK</creatorcontrib><creatorcontrib>SAHL, RONNI EG</creatorcontrib><creatorcontrib>KRIEGBAUM, MARGIT</creatorcontrib><creatorcontrib>LARSEN, STEEN</creatorcontrib><creatorcontrib>DELA, FLEMMING</creatorcontrib><creatorcontrib>HELGE, JØRN WULFF</creatorcontrib><title>Aerobic Exercise Performance and Muscle Strength in Statin Users—The LIFESTAT Study</title><title>Medicine and science in sports and exercise</title><addtitle>Med Sci Sports Exerc</addtitle><description>INTRODUCTIONStatins are widely used in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) which can affect muscle function and levels of physical activity. We investigated whether statin-associated myalgia is coupled to impaired aerobic exercise performance including fat oxidation as well as impaired muscle strength.
METHODSA population-based survey (6000 people) was performed to assess the prevalence of statin-associated myalgia in the Danish population. In addition, 64 statin users in primary prevention with myalgia (M; n = 25; 61 ± 1 yr) or without myalgia (NM; n = 37; 63 ± 1 yr) as well as a control group not taking statins (C; n = 20; 60 ± 2 yr) were enrolled in a cross-sectional study where they performed aerobic exercise and muscle strength tests.
RESULTSThe response rate for the survey was 51% and data showed a prevalence of statin-associated myalgia in 19% of responders using statins. The experimental study showed no difference between the groups in aerobic capacity (C, 29 ± 1 mL O2·min·kg; M, 27 ± 1 mL O2·min·kg; NM, 28 ± 1 mL O2·min·kg) or maximal fat oxidation (C, 247 ± 26 mg·min; M, 295 ± 24 mg·min; NM, 279 ± 17 mg·min). Measurements of strength were similar in all three groups including rate of force development (C, 795 ± 56 N·m·s; M, 930 ± 93 N·m·s; NM, 971 ± 57 N·m·s) and leg extension power (C2.6 ± 0.2; M2.3 ± 0.1; NM2.4 ± 0.1 W·kg). All results are mean ± SEM.
CONCLUSIONStatin users in primary prevention experiencing myalgia do not have impaired aerobic exercise performance or muscle strength compared to nonmyalgic statin users or control subjects.</description><subject>Cardiovascular Diseases - prevention & control</subject><subject>Cross-Sectional Studies</subject><subject>Exercise Tolerance - drug effects</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Lipid Metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Muscle Strength - drug effects</subject><subject>Myalgia - chemically induced</subject><subject>Myosin Heavy Chains - metabolism</subject><subject>Primary Prevention</subject><subject>Simvastatin - adverse effects</subject><subject>Simvastatin - pharmacology</subject><issn>0195-9131</issn><issn>1530-0315</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtOwzAQhi0EoqVwA4SyZJPiV17LqmqhUiuQkq4tx5mQQB7FTlS64xCckJNg1IIQC2YzY_v7x9KH0CXBY0J5dLOK4zH-VSSi-AgNicewixnxjtHQ3nluRBgZoDNjniwUMEZO0YARSrDPwyFaT0C3aamc2StoVRpwHkDnra5lo8CRTeaseqMqcOJOQ_PYFU7Z2Fl2tq0NaPPx9p4U4CwX81mcTBL71me7c3SSy8rAxaGP0Ho-S6Z37vL-djGdLF3FMcUuBaVSkuUp4IjjIPAie8Ye48Tn3Pdzghl4nEAUSEYh5X6KQ0sxrGQQqBCzEbre793o9qUH04m6NAqqSjbQ9kZQymlIQ0a5RfkeVbo1RkMuNrqspd4JgsWXUGGFir9Cbezq8EOf1pD9hL4NWiDcA9u26qyP56rfghYFyKor_t_9CcbngLY</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>MORVILLE, THOMAS</creator><creator>DOHLMANN, TINE LOVSØ</creator><creator>KUHLMAN, ANJA BIRK</creator><creator>SAHL, RONNI EG</creator><creator>KRIEGBAUM, MARGIT</creator><creator>LARSEN, STEEN</creator><creator>DELA, FLEMMING</creator><creator>HELGE, JØRN WULFF</creator><general>American College of Sports Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201907</creationdate><title>Aerobic Exercise Performance and Muscle Strength in Statin Users—The LIFESTAT Study</title><author>MORVILLE, THOMAS ; DOHLMANN, TINE LOVSØ ; KUHLMAN, ANJA BIRK ; SAHL, RONNI EG ; KRIEGBAUM, MARGIT ; LARSEN, STEEN ; DELA, FLEMMING ; HELGE, JØRN WULFF</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4020-2eccb1dfbe09407759ccb0534164466f103e541e97a32eb46b0877530ca77c803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cardiovascular Diseases - prevention & control</topic><topic>Cross-Sectional Studies</topic><topic>Exercise Tolerance - drug effects</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Lipid Metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Muscle Strength - drug effects</topic><topic>Myalgia - chemically induced</topic><topic>Myosin Heavy Chains - metabolism</topic><topic>Primary Prevention</topic><topic>Simvastatin - adverse effects</topic><topic>Simvastatin - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MORVILLE, THOMAS</creatorcontrib><creatorcontrib>DOHLMANN, TINE LOVSØ</creatorcontrib><creatorcontrib>KUHLMAN, ANJA BIRK</creatorcontrib><creatorcontrib>SAHL, RONNI EG</creatorcontrib><creatorcontrib>KRIEGBAUM, MARGIT</creatorcontrib><creatorcontrib>LARSEN, STEEN</creatorcontrib><creatorcontrib>DELA, FLEMMING</creatorcontrib><creatorcontrib>HELGE, JØRN WULFF</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medicine and science in sports and exercise</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MORVILLE, THOMAS</au><au>DOHLMANN, TINE LOVSØ</au><au>KUHLMAN, ANJA BIRK</au><au>SAHL, RONNI EG</au><au>KRIEGBAUM, MARGIT</au><au>LARSEN, STEEN</au><au>DELA, FLEMMING</au><au>HELGE, JØRN WULFF</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aerobic Exercise Performance and Muscle Strength in Statin Users—The LIFESTAT Study</atitle><jtitle>Medicine and science in sports and exercise</jtitle><addtitle>Med Sci Sports Exerc</addtitle><date>2019-07</date><risdate>2019</risdate><volume>51</volume><issue>7</issue><spage>1429</spage><epage>1437</epage><pages>1429-1437</pages><issn>0195-9131</issn><eissn>1530-0315</eissn><abstract>INTRODUCTIONStatins are widely used in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) which can affect muscle function and levels of physical activity. We investigated whether statin-associated myalgia is coupled to impaired aerobic exercise performance including fat oxidation as well as impaired muscle strength.
METHODSA population-based survey (6000 people) was performed to assess the prevalence of statin-associated myalgia in the Danish population. In addition, 64 statin users in primary prevention with myalgia (M; n = 25; 61 ± 1 yr) or without myalgia (NM; n = 37; 63 ± 1 yr) as well as a control group not taking statins (C; n = 20; 60 ± 2 yr) were enrolled in a cross-sectional study where they performed aerobic exercise and muscle strength tests.
RESULTSThe response rate for the survey was 51% and data showed a prevalence of statin-associated myalgia in 19% of responders using statins. The experimental study showed no difference between the groups in aerobic capacity (C, 29 ± 1 mL O2·min·kg; M, 27 ± 1 mL O2·min·kg; NM, 28 ± 1 mL O2·min·kg) or maximal fat oxidation (C, 247 ± 26 mg·min; M, 295 ± 24 mg·min; NM, 279 ± 17 mg·min). Measurements of strength were similar in all three groups including rate of force development (C, 795 ± 56 N·m·s; M, 930 ± 93 N·m·s; NM, 971 ± 57 N·m·s) and leg extension power (C2.6 ± 0.2; M2.3 ± 0.1; NM2.4 ± 0.1 W·kg). All results are mean ± SEM.
CONCLUSIONStatin users in primary prevention experiencing myalgia do not have impaired aerobic exercise performance or muscle strength compared to nonmyalgic statin users or control subjects.</abstract><cop>United States</cop><pub>American College of Sports Medicine</pub><pmid>31210648</pmid><doi>10.1249/MSS.0000000000001920</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-9131 |
| ispartof | Medicine and science in sports and exercise, 2019-07, Vol.51 (7), p.1429-1437 |
| issn | 0195-9131 1530-0315 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2242828324 |
| source | MEDLINE; Journals@Ovid LWW Legacy Archive; Journals@Ovid Complete |
| subjects | Cardiovascular Diseases - prevention & control Cross-Sectional Studies Exercise Tolerance - drug effects Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Lipid Metabolism Male Middle Aged Muscle Strength - drug effects Myalgia - chemically induced Myosin Heavy Chains - metabolism Primary Prevention Simvastatin - adverse effects Simvastatin - pharmacology |
| title | Aerobic Exercise Performance and Muscle Strength in Statin Users—The LIFESTAT Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T05%3A11%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aerobic%20Exercise%20Performance%20and%20Muscle%20Strength%20in%20Statin%20Users%E2%80%94The%20LIFESTAT%20Study&rft.jtitle=Medicine%20and%20science%20in%20sports%20and%20exercise&rft.au=MORVILLE,%20THOMAS&rft.date=2019-07&rft.volume=51&rft.issue=7&rft.spage=1429&rft.epage=1437&rft.pages=1429-1437&rft.issn=0195-9131&rft.eissn=1530-0315&rft_id=info:doi/10.1249/MSS.0000000000001920&rft_dat=%3Cproquest_cross%3E2242828324%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242828324&rft_id=info:pmid/31210648&rfr_iscdi=true |